Abbreviations used: CHX, cycloheximide; DED, death effector domain; DISC, death-inducing signaling complex; EMSA, electrophoretic mobility shift assay; IKK, IκB kinase complex; siRNA, small interfering RNA.

c-FLIP is a well-described inhibitor of death receptor--mediated apoptosis ([@bib1]). At the mRNA level, it can be found in multiple splice variants, whereas at the protein level only three isoforms, c-FLIP~L~, c-FLIP~S~, and c-FLIP~R~, have been detected so far ([@bib1]--[@bib4]). All three c-FLIP isoforms contain two death effector domains (DEDs), which are structurally similar to the NH~2~-terminal part of procaspase-8. c-FLIP~L~ also contains catalytically inactive caspase-like domains (p20 and p12).

c-FLIP proteins are recruited to the death-inducing signaling complex (DISC) by DED interactions ([@bib3]--[@bib5]). Both short c-FLIP isoforms, c-FLIP~S~ and c-FLIP~R~, block death receptor--induced apoptosis by inhibiting procaspase-8 activation at the DISC ([@bib2], [@bib3]). The role of c-FLIP~L~ at the DISC is still a matter of controversy ([@bib6], [@bib7]). Some reports describe c-FLIP~L~ as an antiapoptotic molecule, functioning in a way analogous to c-FLIP~S~, whereas others describe c-FLIP~L~ as a proapoptotic molecule, facilitating the activation of procaspase-8 at the DISC. This proapoptotic role may explain the phenotype of c-FLIP--deficient mice characterized by heart failure and death at embryonic day 10.5. The same phenotype has been reported for caspase-8-- and FADD-deficient mice ([@bib8]--[@bib11]).

In addition to its antiapoptotic role in death receptor--induced apoptosis, c-FLIP proteins were invoked to play a prominent role in NF-κB signaling ([@bib12]--[@bib14]). The transcription factor NF-κB family regulates the expression of genes crucial for innate and adaptive immune responses, cell growth, and apoptosis ([@bib15]). In mammalian cells, the NF-κB family is composed of five members: RelA, RelB, c-Rel, p50/NF-κB1, and p52/NF-κB2 ([@bib16]). In most cells, the NF-κB dimer is sequestered in the cytosol by inhibitors of the κB protein (IκB), and its nuclear translocation can be induced by a wide variety of stimuli ([@bib16]). These stimuli trigger activation of the IκB kinase (IKK) complex, which consists of two catalytic subunits, IKKα and IKKβ, as well as a regulatory subunit, IKKγ/NEMO. When the IKK complex is activated, IκB is phosphorylated, and the IκBs are degraded in a ubiquitin-dependent manner. The NF-κB dimers can then be translocated into the nucleus, where target gene transcription is induced.

Recently, it has been demonstrated that overexpression of c-FLIP~L~ activates NF-κB ([@bib13], [@bib17]). In another study, upon overexpression, c-FLIP~L~ was shown to interact with established components of the TNFR-mediated NF-κB activation pathway, TRAF1, TRAF2, and RIP ([@bib12]). In addition, it has been reported that c-FLIP~L~--mediated NF-κB activation requires cleavage to p43-FLIP, also demonstrated to interact with TRAF2 ([@bib18]). In TNFR-mediated NF-κB activation, TRAF2 and RIP were described to act upstream of the IKK complex ([@bib19], [@bib20]).

Here, we show that in nonapoptotic cells, c-FLIP forms heterodimers with procaspase-8 resulting in a novel NH~2~-terminal fragment of c-FLIP (p22-FLIP). p22-FLIP turned out to be the key mediator of NF-κB activation by direct binding to the IKK complex. These findings provide a new mechanism of c-FLIP--mediated NF-κB activation and shed light on the regulation of life/death decisions made in lymphocytes.

RESULTS
=======

A new form of c-FLIP can be detected in malignant B and T cells
---------------------------------------------------------------

In addition to the three previously described c-FLIP protein isoforms, c-FLIP~L~, c-FLIP~R~, and c-FLIP~S~ ([@bib2], [@bib3], [@bib21]), we have detected a new prominent protein band with the anti-FLIP mAb NF6 directed against the DED region of c-FLIP ([Fig. 1 A](#fig1){ref-type="fig"}). The molecular mass of this protein is ∼22 kD. The p22 protein was observed in total cellular lysates ([Fig. 1 A](#fig1){ref-type="fig"}) and in immunoprecipitates ([Fig. 1 B](#fig1){ref-type="fig"}) from B lymphoblastoid cell lines Boe^R^ and Raji and the T cell lines HUT78 and Jurkat A3, but not in CEM and SKW6.4 cells. The viability of the cells used for analysis was verified by negative propidium iodide and annexin V staining (Fig. S1, available at <http://www.jem.org/cgi/content/full/jem.20051556/DC1>). P22 protein was the most prominent in Boe^R^ cells ([Fig. 1, A and B](#fig1){ref-type="fig"}). We call this protein p22-FLIP.

![**Caspase-dependent presence of p22-FLIP in tumor cell lines.** (A) Total cellular lysates of the indicated T and B cell lines were subjected to 12% SDS-PAGE and Western blot analysis using the anti-FLIP mAb NF6. The positions of c-FLIP~L~, c-FLIP~S/R~, and p22-FLIP are indicated. (B) Western blot analysis of c-FLIP proteins after immunoprecipitation from various cell lines (5 × 10^7^ cells each) using anti-FLIP mAb NF6. Positions of c-FLIP~S/R~ and p22-FLIP are indicated. (C) HUT78 and Jurkat A3 cells were preincubated with or without 20 μM zVAD-fmk for 30 min. Analysis of c-FLIP proteins by Western blot was performed as in A. (D) Schematic representation of c-FLIP proteins. DEDs are depicted in black. The cleavage site for generation of p22-FLIP (D198) is shown. The epitope for anti--c-FLIP mAb NF6 is indicated. (E) The NH~2~ terminus of c-FLIP encoding the amino acids 1--198 was in vitro translated, \[^35^S\] labeled, and added in the indicated amounts to the lysates of Boe^R^ cells as well as to immunoprecipitates of c-FLIP from 5 × 10^7^ Boe^R^ cells.](jem2031295f01){#fig1}

The detection of p22-FLIP with the anti-FLIP mAb NF6 indicated the presence of DEDs in p22-FLIP because the antibody was raised against the NH~2~ terminus of c-FLIP. Furthermore, p22-FLIP disappeared upon the addition of zVAD-fmk ([Fig. 1 C](#fig1){ref-type="fig"}). This suggests that p22-FLIP is likely a caspase-dependent cleavage product of c-FLIP. We then analyzed the primary structure of c-FLIP~L/S~ and found an aspartate residue at position 198 ([Fig. 1 D](#fig1){ref-type="fig"}). Cleavage at Asp^198^ could result in the formation of an NH~2~-terminal DED-containing cleavage product with a molecular mass of ∼22 kD, corresponding to p22-FLIP.

To test this hypothesis, we generated a cDNA corresponding to the c-FLIP NH~2~-terminal fragment resulting from cleavage at Asp^198^. Subsequently, p22-FLIP was translated in vitro and added to cell lysates of Boe^R^ cells, followed by immunoprecipitation with the anti-FLIP mAb NF6. The products of immunoprecipitation as well as the corresponding lysates were analyzed by Western blot ([Fig. 1 E](#fig1){ref-type="fig"}). After adding the in vitro--translated c-FLIP NH~2~-terminal fragment, the band corresponding to p22-FLIP increased considerably. Thus, we conclude that the molecular mass of the in vitro--translated product was indeed identical to endogenous p22-FLIP. These data provide the first evidence that p22-FLIP is an NH~2~-terminal cleavage product of c-FLIP generated by cleavage at Asp^198^.

p22-FLIP identification as the NH~2~-terminal cleavage product of c-FLIP
------------------------------------------------------------------------

To study whether p22-FLIP can be generated from both c-FLIP~L~ and c-FLIP~S~, we performed the following experiment in vitro. c-FLIP~L~, c-FLIP~S~, and FLAG-c-FLIP~L~ were translated in vitro, \[^35^S\] labeled, and added to total cellular lysates of HUT78 and J16 cells ([Fig. 2 A](#fig2){ref-type="fig"}). Upon incubation, all c-FLIPs were cleaved into the NH~2~-terminal fragment p22-FLIP (for c-FLIP~L~ and c-FLIP~S~), the NH~2~-terminal FLAG-p22-FLIP (for FLAG-c-FLIP~L~), and the COOH-terminal fragment p33-FLIP (for c-FLIP~L~ and FLAG-c-FLIP~L~). Consistent with the results obtained previously, p22-FLIP was not detected upon the addition of zVAD-fmk. Thus, we observed a caspase-dependent processing of c-FLIP~L/S~ into p22-FLIP in nonapoptotic cells.

![**Identification of the p22-FLIP cleavage site.** (A) In vitro--translated \[^35^S\]-labeled c-FLIP~S~, c-FLIP~L~, or FLAG-c-FLIP~L~ was added to the lysates of HUT78 (left) and Jurkat A3 cells (right) and incubated overnight at 4°C in presence or absence of 50 μM zVAD-fmk. Reactions were separated on 12% SDS-PAGE gels, blotted, and subjected to autoradiography. (B) In vitro--translated \[^35^S\]-labeled WT-FLAG-c-FLIP~L~ or D198A-FLAG-c-FLIP~L~ was added to the lysates of HUT78 cells and incubated overnight at 4°C in the presence or absence of 50 μM zVAD-fmk and visualized as in A. (C) Boe^R^ cells were transfected with WT-FLAG-c-FLIP~L~ or D198A-FLAG-c-FLIP~L~ and incubated with or without 20 μM zVAD-fmk, and c-FLIP proteins were analyzed by Western blot.](jem2031295f02){#fig2}

To provide conclusive evidence that p22-FLIP is indeed the cleavage product of c-FLIP resulting from cleavage at Asp^198^, we generated an uncleavable D198A mutant of FLAG-c-FLIP~L~. In vitro--translated \[^35^S\]-labeled D198A-FLAG-c-FLIP~L~ and WT-FLAG-c-FLIP~L~ were added to the lysates of HUT78 cells ([Fig. 2 B](#fig2){ref-type="fig"}). As anticipated, FLAG-p22-FLIP was generated in a caspase-dependent manner only from WT-FLAG-c-FLIP. In addition, Boe^R^ cells were transfected with WT- and D198A-FLAG-c-FLIP constructs, and consistent with the in vitro data, FLAG-p22-FLIP generation was observed only in the cells transfected with the WT construct ([Fig. 2 C](#fig2){ref-type="fig"}). Collectively, these data demonstrate that p22-FLIP is the NH~2~-terminal cleavage product of c-FLIP generated by caspase cleavage at Asp^198^.

p22-FLIP is generated by procaspase-8 activity and inhibits death receptor--induced apoptosis
---------------------------------------------------------------------------------------------

To unravel the mechanism of p22-FLIP formation and find the caspase directly involved in c-FLIP processing, we investigated whether procaspase-8 might generate p22-FLIP. Procaspase-8, which, as a proform, was reported to possess catalytic activity ([@bib7], [@bib22]) and form heterodimers with c-FLIP in the cytosol by DED interactions, represented a likely candidate ([@bib6], [@bib23]). Therefore, we immunoprecipitated procaspase-8 from HUT78 cells with an anti--caspase-8 mAb and added in vitro--translated \[^35^S\]-labeled c-FLIP~L~ ([Fig. 3 A](#fig3){ref-type="fig"}, left). Interestingly, we observed cleavage of c-FLIP~L~ into the NH~2~-terminal fragment p22-FLIP and the COOH-terminal fragment p33-FLIP by procaspase-8. The processing was blocked by zVAD-fmk.

![**p22-FLIP is generated by procaspase-8 and inhibits death receptor--induced apoptosis.** (A) Procaspase-8 was immunoprecipitated from HUT78 cells using anti--caspase-8 mAb C15 and then incubated for 1 h at 37°C together with in vitro--translated \[^35^S\]-labeled c-FLIP~L~ in the presence or absence of zVAD-fmk. c-FLIP processing was analyzed by autoradiography (top left). c-FLIP cleavage products p22 and p33 are indicated. Afterward, the same membrane was subjected to Western blot analysis using anti--caspase-8 mAb C15 (bottom left). \[^35^S\]-labeled c-FLIP~L~ was incubated with the indicated concentrations of recombinant caspase-8 for 1 h at 37°C. c-FLIP processing was analyzed byautoradiography (top right). c-FLIP cleavage products p12 and p43 are indicated. Afterward, the same membrane was subjected to Western blot analysis using anti--caspase-8 mAb C15 (bottom right). (B) Analysis of p22-FLIP expression in BJAB cell lines stably overexpressing high or low amounts of p22-FLIP (p22-FLIP~high~ or p22-FLIP~low~, respectively). Endogenous expression of c-FLIP~S~ is used as a loading control. (C) p22-FLIP~high~, p22-FLIP~low~, and vector-transfected BJABs (Ctrl.) were stimulated with 1 μg/ml anti--APO-1 antibodies or 50 μl/ml LZ-CD95L for 16 h. Specific cell death was calculated as described in Materials and methods. (D) p22-FLIP~high~, p22-FLIP~low~, and vector-transfected BJABs (Ctrl.) were stimulated with the indicated concentrations of FLAG-TRAIL for 16 h. (E) CD95 DISCs were immunoprecipitated from 5 × 10^7^ cells of p22-FLIP~high~ and vector-transfected BJABs (Ctrl.) and analyzed by Western blot with anti--caspase-8 mAb C15, anti-FLIP mAb NF6, anti-CD95 polyclonal antibody C20, and anti-FADD mAb.](jem2031295f03){#fig3}

To ensure that the mature caspase-8 heterotetramer could not process c-FLIP into p22-FLIP, we added recombinant active caspase-8 to in vitro--translated c-FLIP~L~ ([Fig. 3 A](#fig3){ref-type="fig"}, right). As expected, recombinant caspase-8 cleaves c-FLIP~L~ in a "classic apoptotic" fashion and generated p43-FLIP and p12-FLIP. Thus, we show that caspase-8 and procaspase-8 process c-FLIP in two mutually exclusive ways. The active caspase-8 heterotetramer generates the well-characterized p43-FLIP and p12-FLIP cleavage products, whereas procaspase-8 activity induces formation of the novel p22-FLIP cleavage product as well as the COOH-terminal p33-FLIP. This is consistent with a report on different substrate specificities of the caspase-8 proform and active caspase-8 ([@bib7]). Clearly, the present study is the first to demonstrate two different caspase-8 specificities with respect to c-FLIP cleavage.

c-FLIP proteins are well-established inhibitors of death receptor--mediated apoptosis. To examine the role of p22-FLIP in death receptor--mediated apoptosis, we generated stable BJAB cell lines overexpressing either high (p22-FLIP~high~) or low (p22-FLIP~low~) amounts of p22-FLIP. The amount of p22-FLIP in these cell lines was validated by Western blot ([Fig. 3 B](#fig3){ref-type="fig"}). Both p22-FLIP~high~ and p22-FLIP~low~ BJAB cells were characterized by reduced sensitivity toward CD95- and TRAIL-induced apoptosis as compared with the vector-transfected control ([Fig. 3](#fig3){ref-type="fig"}, C and D, respectively). The reduction in apoptosis was more prominent in the p22-FLIP~high~ cells. These data provide evidence that compared with other c-FLIP proteins, p22-FLIP is an even stronger inhibitor of death receptor--induced apoptosis.

c-FLIP proteins were reported to have a short half-life ([@bib24], [@bib25]). We and others have demonstrated that cycloheximide (CHX) sensitizes cells toward death receptor--induced apoptosis, which correlates with a decrease of c-FLIP levels ([@bib24], [@bib25]). To understand whether sensitization also involves a decrease of the p22-FLIP level, we studied Boe^[r]{.smallcaps}^ cells that contain high levels of p22-FLIP. Treatment of Boe^[r]{.smallcaps}^ cells with CHX resulted in a substantial decrease of the p22-FLIP level within 4 h (Fig. S2 A, available at <http://www.jem.org/cgi/content/full/jem.20051556/DC1>). This decrease correlated with an enhanced sensitivity toward CD95- and TRAIL-induced apoptosis (Fig. S2 B). These data provide additional evidence that the p22-FLIP level in Boe^[r]{.smallcaps}^ cells correlates with the sensitivity toward death receptor--induced apoptosis, pointing toward the inhibitory role of p22-FLIP.

The antiapoptotic action of c-FLIP in death receptor--mediated apoptosis involves inhibition of caspase-8 activation at the DISC ([@bib2], [@bib3], [@bib24]). To investigate whether p22-FLIP is also recruited to the DISC, we immunoprecipitated the CD95 DISC from p22-FLIP~high~ cells. Indeed, p22-FLIP was recruited to the DISC ([Fig. 3 E](#fig3){ref-type="fig"}). As expected, the activation of procaspase-8 at the DISC of p22-FLIP~high~ cells was lower than in vector-transfected cells. The amount of caspase-8 cleavage products in the DISC, p43/p41, and p18 was markedly reduced in p22-FLIP~high~ cells, whereas the amounts of FADD and CD95 were similar in both p22-FLIP~high~ and vector-transfected cells. This observation is consistent with the reduced sensitivity of p22-FLIP~high~ cells toward CD95-induced apoptosis and shows that p22-FLIP effectively blocks caspase-8 activation at the DISC, thereby inhibiting CD95-induced apoptosis.

p22-FLIP is a strong inducer of NF-κB
-------------------------------------

We established an inhibitory role of p22-FLIP in death receptor--induced apoptosis; however, the questions of why p22-FLIP is present in nonapoptotic malignant cells and which functional role p22-FLIP might play in the nonapoptotic scenario were not answered. Using NF-κB luciferase activation assays with p22-FLIP and c-FLIP~L~, we observed that p22-FLIP is a strong inducer of NF-κB ([Fig. 4 A](#fig4){ref-type="fig"}). Moreover, p22-FLIP--mediated NF-κB activation was much stronger than that observed with c-FLIP~L~, even though expression levels of p22-FLIP and c-FLIP~L~ were similar ([Fig. 4 A](#fig4){ref-type="fig"}).

![**p22-FLIP is a strong inducer of NF-κB.** (A) 293T cells were cotransfected with MEKK1, p22-FLIP, c-FLIP~L~, and luciferase reporter plasmid. GFP transfections were performed to control the transfection efficiency. Western blot analysis using anti-FLIP mAb NF6 was performed to control equal protein expression (right). (B) 293T cells were cotransfected with p22-FLIP and the luciferase reporter plasmid. After the indicated periods of time, cells were lysed and NF-κB luciferase activity was determined (top). Western blot analysis using anti-FLIP mAb NF6 was performed to determine the expression level of p22-FLIP. (C) Nuclear extracts, which were prepared from 293T cells transfected with p22-FLIP or GFP, were subjected to EMSAs using ^32^P-labeled oligonucleotides containing an NF-κB (left) or an NF-Y (right) binding site. p22-FLIP expression was verified by Western blot.](jem2031295f04){#fig4}

To clarify whether NF-κB activation correlates with the expression level of p22-FLIP, we performed transient transfections of 293T cells with p22-FLIP ([Fig. 4 B](#fig4){ref-type="fig"}). The maximum of NF-κB activity at 10 h paralleled the increase of p22-FLIP expression. Moreover, the observed expression level of p22-FLIP in 293T cells ([Fig. 4 B](#fig4){ref-type="fig"}) compared with c-FLIP~L~ was still lower as compared with the ratio p22-FLIP/c-FLIP~L~ in Boe^R^ cells ([Fig. 1 A](#fig1){ref-type="fig"}). Thus, we demonstrate that the induction of NF-κB is specific for p22-FLIP and does not depend on a high expression level of p22-FLIP.

We also assayed p22-induced NF-κB activity by electrophoretic mobility shift assay (EMSA; [Fig. 4 C](#fig4){ref-type="fig"}), which independently confirmed that p22-FLIP induces NF-κB. Thus, we demonstrated that p22-FLIP is a strong inducer of NF-κB.

p22-FLIP induces NF-κB by direct interaction with the IKK complex
-----------------------------------------------------------------

To get more insight into the mechanism of p22-mediated NF-κB induction, we coexpressed p22-FLIP with the inhibitors of NF-κB (IκBα and IκBβ) and with components of the IKK complex (IKKα, IKKβ, DN-IKKα, and DN-IKKβ; [Fig. 5 A](#fig5){ref-type="fig"}). Cotransfections of p22-FLIP with increasing amounts of IκBα and IκBβ inhibited NF-κB activation. Looking at more upstream events, we observed that cotransfection with DN-IKKα and DN-IKKβ also led to suppression of NF-κB activation. Collectively, the results indicated that p22-FLIP is a strong inducer of NF-κB acting via the canonical NF-κB pathway.

![**p22-FLIP induces NF-κB by direct interaction with the IKK complex.** (A) 293T cells were cotransfected with luciferase reporter plasmid and either MEKK1, p22-FLIP, or c-FLIP~L~ (top part of the diagram). 293T cells were cotransfected with p22-FLIP, the luciferase reporter plasmid, and any one of the constructs IκBα, IκBβ, WT-IKKα, WT-IKKβ, mutated IKKα, or IKKβ (bottom part of the diagram). Transfection efficiency was examined using GFP transfections. NF-κB luciferase activity was determined as described in Materials and methods. (B) FLAG or FLIP immunoprecipitations were performed from 293T cells that were transfected with p22-FLIP and any one of the constructs FLAG-IKKα, FLAG-IKKβ, or FLAG-IKKγ. Immunoprecipitated products were subjected to 12% SDS-PAGE gels and analyzed by Western blot using anti-FLIP mAb NF6 and anti-FLAG mAb. (C) 293T cells were cotransfected with MEKK1, p22-FLIP, c-FLIP~L~, p43-FLIP, and the luciferase reporter plasmid. Transfected cells were incubated for 16 h in the presence of the indicated concentrations of zVAD-fmk and lysed, and NF-κB luciferase activity was determined.](jem2031295f05){#fig5}

We further examined whether p22-FLIP directly interacts with the IKK complex. FLAG-tagged IKKα, IKKβ, and IKKγ were transiently cotransfected with p22-FLIP into 293T cells, and then immunoprecipitated with anti-FLAG and anti-FLIP antibodies ([Fig. 5 B](#fig5){ref-type="fig"}). We did not observe any interaction between p22-FLIP and IKKα or IKKβ. However, p22-FLIP was coimmunoprecipitated with FLAG-IKKγ and vice versa. Thus, we showed that p22-FLIP interacts with the IKK complex via IKKγ.

In addition, we compared NF-κB induction by p22-FLIP, c-FLIP~L~, and p43-FLIP upon transient transfections in 293T cells ([Fig. 5 C](#fig5){ref-type="fig"}). Interestingly, the addition of zVAD-fmk resulted in a decrease in NF-κB activation for p43-FLIP and c-FLIP~L~, but did not affect p22-FLIP--mediated NF-κB induction. These results strongly indicate that p43-FLIP and c-FLIP~L~ require further cleavage to induce NF-κB activity, whereas p22-FLIP does not. Thus, we show that for the induction of NF-κB activity, both p43-FLIP and c-FLIP~L~ have to be processed into p22-FLIP.

p22-FLIP induces NF-κB during activation of primary lymphocytes and maturation of primary DCs
---------------------------------------------------------------------------------------------

Next, we examined primary human T and B cells for the presence of p22-FLIP. Interestingly, p22-FLIP was absent in freshly prepared cells, but was generated upon activation of these cells with PHA ([Fig. 6 A](#fig6){ref-type="fig"}). The same phenomenon was observed in DCs. p22-FLIP was generated upon LPS stimulation, indicating that p22-FLIP is present during maturation of DCs ([Fig. 6 A](#fig6){ref-type="fig"}). Also, the increase of p22-FLIP levels in primary cells correlated with the increase of c-FLIP levels and, correspondingly, with the increase of the ratio of c-FLIP to procaspase-8. This observation provides additional evidence for the proposed mechanism of procaspase-8--mediated c-FLIP cleavage to p22-FLIP ([Fig. 3](#fig3){ref-type="fig"}).

![**p22-FLIP is a key mediator of NF-κB induction.** (A) Primary human T and B cells were stimulated with 1 μg/ml PHA. Primary immature iDCs were stimulated with 500 ng/ml LPS. Western blot analysis was performed using the anti-FLIP mAb NF6, the anti--caspase-8 mAb C15, and the anti-ERK1 mAb. (B) 10^7^ primary human T cells were stimulated with 1 μg/ml PHA for 12 h and lysed, and anti-IKKγ immunoprecipitation was performed. Western blot analysis was performed using anti-IKKα/β antibody and anti-FLIP mAb NF6. (C) Primary human T cells were transiently transfected with double-stranded siRNA oligonucleotides comprising a FLIP-specific sequence (FLIP-1) or a nonspecific sequence (Ctrl.). 48 h after transfection, cells were stimulated with 1 μg/ml PHA for 3 d (right) or 0.5 μg/ml anti-CD3/28 for 24 h (left) or 3 d (right). After incubation, cells were lysed and Western blot analysis was performed using the anti-FLIP mAb NF6 (left), or the proliferation was measured after incorporation of tritiated thymidine (\[^3^H\]TdR) during the last 18 h.](jem2031295f06){#fig6}

To find out whether p22-FLIP also directly interacts with the IKK complex in primary human T cells, we performed immunoprecipitations using an anti-IKKγ antibody ([Fig. 6 B](#fig6){ref-type="fig"}). We observed p22-FLIP in the IKK complex. Thus, we conclude that p22-mediated NF-κB induction occurs via the same mechanism in primary cells.

To obtain more insight into the role of p22-FLIP in T cell activation, we studied the proliferation of primary T cells upon silencing of c-FLIP using small interfering RNA (siRNA). The silencing of c-FLIP resulted in down-regulation of c-FLIP~L/S/R~ as well as its cleavage product, p22-FLIP ([Fig. 6 C](#fig6){ref-type="fig"}). Primary T cells were stimulated with either PHA or anti-CD3/CD28, and thymidine incorporation was measured after 3 d of additional culture ([Fig. 6 C](#fig6){ref-type="fig"}). Interestingly, silencing of c-FLIP led to a complete stop of cell proliferation. Thus, we show that the absence of c-FLIP and, consequently, p22-FLIP led to severe defects in T cell proliferation.

DISCUSSION
==========

c-FLIP proteins were demonstrated to induce NF-κB activation ([@bib12]--[@bib14]). However, the exact underlying mechanism of this process has not been established yet. In this study, we identified a new mechanism of c-FLIP--mediated NF-κB activation and showed that NF-κB activation requires c-FLIP processing into the NH~2~-terminal DED-containing fragment, p22-FLIP ([Fig. 7](#fig7){ref-type="fig"}). p22-FLIP is generated by procaspase-8 cleavage of both c-FLIP isoforms, c-FLIP~L~ and c-FLIP~S~. Furthermore, p22-FLIP is a strong activator of NF-κB, acting directly at the level of the IKK complex by binding to IKKγ. In addition to its role as an activator of NF- κB, p22-FLIP can block apoptosis by directly binding to the DISC.

![**The dual function of p22-FLIP in the cell.** p22-FLIP induces NF-κB by interacting with IKKγ in the IKK complex (right side). In addition, p22-FLIP can block death receptor--mediated apoptosis by binding to the DISC via DED interactions and inhibiting procaspase-8 activation (left side).](jem2031295f07){#fig7}

p22-FLIP is generated by cleavage of c-FLIP~L/S~ at Asp^198^. The resulting NH~2~-terminal fragment, p22-FLIP, contains two tandem DEDs and has a high structural homology to v-FLIP of the Kaposi\'s sarcoma-associated herpesvirus and other v-FLIPs ([@bib14]) that are also characterized by the presence of two DEDs followed by a short COOH terminus.

We argue that p22-FLIP is the final cleavage product of c-FLIP that serves as a mediator of NF-κB activation. This result is in contrast to previous studies, where it was suggested that p43-FLIP is a cleavage product of c-FLIP that mediates NF-κB activation ([@bib18]). We have clearly shown that upon zVAD-fmk treatment, p43-FLIP--mediated activation of NF-κB is decreased, whereas the p22-FLIP--mediated NF-κB response remained unaltered. These results indicate that p43-FLIP requires further processing.

Importantly, our study demonstrates a new NF-κB--activating pathway initiated by procaspase-8. We show that independently of death receptor stimulation, procaspase-8 generates the p22-FLIP cleavage product, which leads to the induction of NF-κB ([Fig. 7](#fig7){ref-type="fig"}). Recently, procaspase-8 was reported to play a prominent role in NF-κB induction via its involvement in the MALT1--Bcl-10 adaptor complex that is formed upon TCR stimulation ([@bib26]). Our findings further elucidate the involvement of procaspase-8 in NF-κB induction.

Interestingly, we could also show that the active mature caspase-8 heterotetramer p10~2~-p18~2~ cleaves c-FLIP~L~ in vitro to p43-FLIP and p12-FLIP, but not to p22-FLIP. Thus, we observe that procaspase-8 and caspase-8 heterotetramer cleave c-FLIP in two different ways. This is consistent with reports upon different substrate specificities of the caspase-8 proform and active caspase-8 ([@bib7]). Of note, our study is the first one demonstrating two different caspase-8 specificities with respect to c-FLIP cleavage.

In addition, we have observed in primary cells that upon increase of the ratio of c-FLIP to procaspase-8, the amount of p22-FLIP was substantially increased. It is likely that procaspase-8 constitutively cleaves c-FLIP to p22-FLIP, forming dimers with c-FLIP. The formation of such dimers between procaspase-8 and c-FLIP in the cytosol was described previously ([@bib6], [@bib23]). Thus, the ratio of procaspase-8 to c-FLIP in a particular cell type would be the crucial factor defining the amount of generated p22-FLIP and, correspondingly, the potential to induce NF-κB.

Our findings provide a molecular mechanism for how c-FLIP and procaspase-8 contribute to the activation and proliferation of primary lymphocytes. It was reported that caspase activity is essential for T cell activation, as it was shown in experiments with caspase inhibitors ([@bib27], [@bib28]). Analysis of caspase-8 and c-FLIP conditional knockout mice has demonstrated that those mice show severe defects in T cell activation and proliferation ([@bib29]). Caspase-8 was reported to be essential for antigen-induced NF-κB activation in T, B, and NK cells ([@bib26], [@bib30], [@bib31]). We show that upon silencing of c-FLIP in primary cells, the proliferation of these cells is impaired. This demonstrates the importance of our new p22-FLIP--mediated NF-κB--activating pathway in primary lymphocytes.

In conclusion, we described a new NF-κB--activating pathway, which is mediated by two well-described apoptotic DED-containing proteins: procaspase-8 and c-FLIP via their cleavage product, p22-FLIP. The balance between DED-containing proteins may provide sensitive signaling check points that cells use for signaling cross-talk and switching between apoptosis-resistant and -sensitive phenotypes and, thus, between life and death.

MATERIALS AND METHODS
=====================

Cell lines.
-----------

The T cell lines HUT78, CEM, H9, Jurkat (clone A3), and Jurkat (clone J16); the B lymphoblastoid cell lines SKW6.4, Raji, and BJAB; and the pre--B cell line Boe^R^ were maintained in RPMI 1640, 10 mM Hepes, 50 μg/ml gentamycin, and 10% fetal calf serum (all from Life Technologies) in 5% CO~2~.

Antibodies and reagents.
------------------------

Anti-FADD mAb (IgG1) was purchased from Transduction Laboratories. Anti-FLAG mAb was purchased from Sigma-Aldrich. Anti-CD95 polyclonal antibody C20 was purchased from Santa Cruz Biotechnology, Inc. Anti--caspase-8 mAb C15 (mouse IgG2b) recognizes the p18 subunit of caspase-8 ([@bib32]). Anti-IKKα/β and anti-IKKγ antibodies were purchased from Santa Cruz Biotechnology, Inc., and anti-ERK1 mAb was purchased from BD Biosciences. Anti--APO-1 is an agonistic mAb (IgG3, κ) recognizing an epitope on the extracellular part of CD95 (APO-1/Fas; reference [@bib33]). FLAG-TRAIL was obtained from H. Walczak (DKFZ, Heidelberg, Germany). Horseradish peroxidase--conjugated goat anti--mouse IgG1, IgG2a, and IgG2b were from SouthernBiotech. All chemicals used were of analytical grade and purchased from Merck or Sigma-Aldrich. Plasmids encoding c-FLIP~L~ and c-FLIP~S~ have been described previously ([@bib2]). The plasmid encoding FLAG-c-FLIP~L~ has also been described ([@bib3]). NF-κB reporter plasmid was provided by M. Li-Weber (DKFZ, Heidelberg, Germany). Constructs of FLAG-IKKα, FLAG-IKKβ, DN-FLAG-IKKα (K44A), and DN-FLAG-IKKβ (K44A) were provided by H. Nakano (Juntendo University, Tokyo, Japan).

EMSA.
-----

Soluble nuclear proteins were prepared and used for EMSA as described previously ([@bib34]). For each reaction, 10--20 fmol of ^32^P-labeled oligonucleotides comprising an NF-κB binding site (5′-TCAGAGGGGACTTTCCGAGAGGCG-3′) or NF-Y binding site (5′-CACCTTTTAACCAATCAGAAAAAT-3′) were used.

Cloning of p22-FLIP and D198A-FLAG-c-FLIP~L~.
---------------------------------------------

p22-FLIP was cloned into the pEF4 expression vector (Invitrogen) using the PCR and the following primers: sense (encoding the KpnI restriction site): 5′-ggggtaccccATGTCTGCTGAAGTCATCC-3′ and antisense (encoding the XbaI restriction site): 5′-gctctagagcctaATCCTTGAGACTCTTTTGG-3′.

The D198A-FLAG-c-FLIP~L~ mutant was cloned via overlap-PCR into the pEF4 expression vector (Invitrogen). The NH~2~-terminal part was amplified using the following: forward primer 1: 5′-ggggtaccccATGGACTACAAGGACGACGACAAGGGGATGTCTGCTGAAGTCATCCATCAGG-3′; reverse primer 1: 5′-CCTGAAAGTTATTTGAAGGTGCCTTGAGACTCTTTTGG-3′. The COOH-terminal part was amplified using the following: reverse primer 2: 5′-gctctagagcCTATGTGTAGGAGAGGATAAG-3′; forward primer 2: 5′-CCAAAAGAGTCTCAAGGCACCTTCAAATAACTTCAGG-3′. The overlap-PCR was performed using the forward and reverse primer 2.

CD95 DISC analysis.
-------------------

Composition of the CD95 DISC was determined as follows. 5 × 10^7^ cells were treated either with 1 μg/ml anti--APO-1 (IgG3) for 5 min at 37°C or left untreated, washed twice in 1× PBS, and lysed in lysis buffer (30 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride \[Sigma-Aldrich\], protease inhibitor cocktail \[Roche\], 1% Triton X-100 \[Serva\], and 10% glycerol). If pretreated with zVAD-fmk, cells were preincubated for 30 min at 37°C with the indicated concentrations of zVAD-fmk before stimulation. CD95 was immunoprecipitated with anti--APO-1 and protein A--Sepharose beads (Sigma-Aldrich) overnight at 4°C. Beads were washed five times with 20 volumes of lysis buffer. Immunoprecipitates were used for in vitro assay or analyzed using SDS-PAGE gels ([@bib35]). Gels were transferred to Hybond nitrocellulose membrane (GE Healthcare), blocked with 5% nonfat dry milk in PBS/Tween (PBS plus 0.05% Tween 20) for 1 h, washed with PBS/Tween, and incubated with the primary antibody in PBS/Tween overnight at 4°C. Blots were developed with a chemoluminescence method according to the manufacturer\'s protocol (PerkinElmer).

Immunoprecipitations.
---------------------

For c-FLIP immunoprecipitation, 5 × 10^7^ cells were lysed in a volume of 1 ml for 30 min at 0°C, followed by the addition of 100 μl NF6 hybridoma supernatant together with 30 μl protein A--Sepharose. For FLAG immunoprecipitation, 2 × 10^6^ cells were transfected using the calcium phosphate method 1 d before lysis. Immunoprecipitation was performed by using 4 μg anti-FLAG mAb together with 30 μl protein A--Sepharose. For IKKγ immunoprecipitation, 10^7^ primary human T cells were lysed with or without stimulation, and the immunoprecipitation was performed by using 2 μg anti-IKKγ mAb together with 30 μl protein A-- Sepharose. Immunoprecipitations were performed for 1 h at room temperature or overnight at 4°C. Beads were then washed five times with 20 volumes of lysis buffer and subjected to Western blot analysis as described above.

In vitro c-FLIP cleavage assays.
--------------------------------

Lysates of the indicated cell lines were prepared as described above and incubated with in vitro--translated \[^35^S\]-labeled c-FLIP~L~, FLAG-c-FLIP~L~, D198A-FLAG-c-FLIP~L~, or c-FLIP~S~ (TNT, T7-coupled reticulocyte lysate system; Promega) overnight at 4°C ([@bib36]). The procaspase-8 cleavage assay was performed as follows: 5 × 10^7^ HUT78 cells were lysed, and procaspase-8 was immunoprecipitated using 100 μl anti--caspase-8 C15 hybridoma together with 30 μl protein A--Sepharose. Beads with bound procaspase-8 were incubated in reaction buffer (50 mM Hepes, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM dithiothreitol, and 10% sucrose) for 1 h at 37°C together with in vitro--translated c-FLIP~L~. The recombinant caspase-8 cleavage assay was performed as follows: 5 or 50 ng/ml recombinant caspase-8 was incubated in reaction buffer for 1 h at 37°C together with in vitro--translated c-FLIP~L~. Reactions were separated on 12% SDS-PAGE gels, blotted, and subjected to autoradiography.

Transfection of BJAB and Boe^R^ cells.
--------------------------------------

Stable transfection of BJAB as well as transient transfection of Boe^R^ cells was performed using expression vectors or the empty vector by electroporation (950 μF, 200 V). Selection pressure was added 48 h after transfection (100 μg/ml zeocin) for 2 wk (BJAB cells) or 10 d (Boe^R^ cells). Expression was controlled by Western blot using anti-FLIP mAb NF6. The p22-FLIP--expressing BJABs as well as the empty vector--transfected control cells were subcloned.

Cytotoxicity assay.
-------------------

To assay apoptosis, 5 × 10^5^ cells were incubated in 48-well plates with or without the indicated amounts of anti--APO-1, LZ- CD95L, or FLAG-TRAIL for 16 h at 37°C. Cell death was measured by FSC/SSC via flow cytometry, and specific cell death was calculated as follows: (percentage of experimental cell death − percentage of spontaneous cell death)/(100 − percentage of spontaneous cell death) × 100.

NF-κB activation assay.
-----------------------

The day before transfection, 24-well titer plates were seeded with 0.5 × 10^5^ 293T cells. The cells were transfected using the calcium phosphate method with various expression vectors together with 500 ng of the NF-κB--driven luciferase reporter plasmid. Cells were washed with PBS 16 h after transfection and lysed for 20 min at room temperature in 50 μl lysis buffer (passive lysis buffer; Promega), followed by centrifugation (10,000 *g*) for 20 min to sediment insoluble materials. A total of 5 μl of cell lysates was mixed with 50 μl of the luciferase assay mixture (470 μM Beetle Luciferin \[Promega\], 1.07 mM (MgCO~3~)~4~Mg(OH)~2~ × 5 H~2~O, 20 mM *N*-Tris-(hydroxymethyl)-methylglycine, 2.67 mM MgSO~4~, 100 μM EDTA, 33.3 mM DTT, 270 μM CoA(OAc), and 530 μM ATP), and relative light units were measured with a Berthold duoluminomat (Bad Wildbad).

Preparation and activation of primary human lymphocytes and DCs.
----------------------------------------------------------------

Human peripheral T and B cells were prepared as described previously ([@bib37]). For activation, resting primary human T cells (day 0) were cultured at 2 × 10^6^ cells/ml with 1 μg/ml PHA for 16 h (day 1), and primary human B cells (day 0) were cultured at 2 × 10^6^ cells/ml with 2 μg/ml PHA. After preparing lymphocytes, the primary human monocytes were isolated using cell adhesion onto cell culture flasks. Leukocytes were resuspended in 20--30 ml RPMI 1640 with 10% FCS, and 2-ml aliquots were seeded into six-well titer plates. After incubation for 1 h, adherent cells were washed with PBS. Monocytes were differentiated into immature DCs by adding 1% human AB serum, 1% donor plasma, 1,000 U/ml GM-CSF (Schering), and 500 U/ml IL-4 (Immunotools) for 3 d. Cytokines were renewed after 3 d for an additional 3 d, and immature DCs were stimulated with 500 ng/ml LPS for 16 h.

CHX experiments.
----------------

For CHX treatments, cells were incubated with 10 μg/ml CHX for the indicated periods of time. For assaying apoptosis in a cytotoxicity assay, 10^6^ cells were pretreated with 10 μg/ml CHX for 4 h, washed, and incubated with the indicated concentrations of 1 μg/ml anti-- APO-1 or 50 ng/ml FLAG-TRAIL for 16 h at 37°C in 24-well plates. Cell death was measured by FSC/SSC via flow cytometry, and specific cell death was calculated as follows: (percentage of experimental cell death − percentage of spontaneous cell death)/(100 − percentage of spontaneous cell death) × 100.

Annexin V and propidium iodide staining.
----------------------------------------

To detect phosphatidylserine exposure by flow cytometry, the T and B cell lines were washed once with PBS, incubated for 10 min on ice in 400 μl binding buffer (2.5 mM Hepes--NaOH, pH 7.4, 35 mM NaCl, and 0.625 mM CaCl~2~) with 1 μl annexin V--FITC (Qbiogene) or 10 μg/ml propidium iodide (Invitrogen), and analyzed via flow cytometry.

siRNA-mediated knockdown of c-FLIP and proliferation assays.
------------------------------------------------------------

Primary human T cells were transfected by HiPerfect (QIAGEN) with a negative control or siRNA oligonucleotids specific for human CFLAR (Hs_CFLAR_1 HP; QIAGEN). For the lipofection, 0.2 μg (75 nM) siRNA was used, and transfected cells were rested for 48 h before further analysis. For proliferation assays, 10^5^ cells were seeded into a 96-well titer plate and stimulated with either 1 μg/ml PHA or 0.5 μg/ml each of anti-CD3/CD28 for up to 4 d. Proliferation was measured with a scintillation counter after tritiated thymidine (\[^3^H\]TdR) incorporation during the final 15--18 h of the culture.

Online supplemental material.
-----------------------------

Fig. S1 shows the living status of tumor cell lines used, and Fig. S2 shows that the resistance of Boe^R^ cells toward CD95- or TRAIL-induced apoptosis is mediated by c-FLIP. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20051556/DC1>.

Supplemental Material
=====================
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